May 22, 2025
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage…
Pharmaceuticals, Biotechnology and Life Sciences
Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage…
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient…
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company…
– Virtual KOL Event Tuesday, June 3, 2025 3:00pm ET – – Attend the event here: https://lifescievents.com/event/immix-asco – LOS ANGELES,…
TORONTO, May 21, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (“MediPharm” or the “Company”), a pharmaceutical company specialized…
Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders’…
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies OSE Immunotherapeutics to lead French consortium with Inside Therapeutics and…
Press Release – Approval of all resolutions submitted by the Board of Directors, including the unconsolidated and consolidated financial statements…
MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better…
Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate…